{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:07:14Z","timestamp":1772280434572,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,28]]},"DOI":"10.7759\/cureus.104428","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:20:05Z","timestamp":1772274005000},"source":"Crossref","is-referenced-by-count":0,"title":["Triple-Dose Furmonertinib for Leptomeningeal Metastases in Advanced Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Hong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan G","year":"2023","unstructured":"Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res. 2023, 29:11-29. 10.1158\/1078-0432.CCR-22-1585","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-1006","article-title":"Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial","volume":"14","author":"Bortolot M","year":"2025","unstructured":"Bortolot M, Huijs JW, Brandsma D, Compter A, van Geel RM, Hendriks LE. Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial. Transl Lung Cancer Res. 2025, 14:7-13. 10.21037\/tlcr-24-1006","journal-title":"Transl Lung Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101832","article-title":"Therapeutic role of EGFR - tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis","volume":"39","author":"Jia C","year":"2024","unstructured":"Jia C, Xu Q, Zhao L, Kong F, Jia Y. Therapeutic role of EGFR - tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. Transl Oncol. 2024, 39:101832. 10.1016\/j.tranon.2023.101832","journal-title":"Transl Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001492","article-title":"Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer","volume":"10","author":"Batra U","year":"2023","unstructured":"Batra U, Biswas B, Prabhash K, Krishna MV. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res. 2023, 10:10.1136\/bmjresp-2022-001492","journal-title":"BMJ Open Respir Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (Blossom)","volume":"42","author":"Park S","year":"2024","unstructured":"Park S, Baldry R, Jung HA, et al.. Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (Blossom). J Clin Oncol. 2024, 42:2747-56. 10.1200\/JCO.24.00708","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1385","article-title":"High-dose Furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study","volume":"20","author":"Chen H","year":"2025","unstructured":"Chen H, Yang S, Wang L, et al.. High-dose Furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study. J Thorac Oncol. 2025, 20:65-75. 10.1016\/j.jtho.2024.09.1385","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017, 67:93-9. 10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70088","article-title":"Chinese expert consensus on leptomeningeal metastases of lung cancer","volume":"16","author":"Lin G","year":"2025","unstructured":"Lin G, Wang Y, Xin T, et al.. Chinese expert consensus on leptomeningeal metastases of lung cancer. Thorac Cancer. 2025, 16:e70088. 10.1111\/1759-7714.70088","journal-title":"Thorac Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5218","article-title":"Targeting CNS metastases in non-small cell lung cancer with evolving approaches using molecular markers: a review","volume":"11","author":"Malhotra J","year":"2025","unstructured":"Malhotra J, Mambetsariev I, Gilmore G, et al.. Targeting CNS metastases in non-small cell lung cancer with evolving approaches using molecular markers: a review. JAMA Oncol. 2025, 11:60-9. 10.1001\/jamaoncol.2024.5218","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment","volume":"174","author":"Wang Y","year":"2022","unstructured":"Wang Y, Yang X, Li NJ, Xue JX. Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment. Lung Cancer. 2022, 174:1-13. 10.1016\/j.lungcan.2022.09.013","journal-title":"Lung Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.1440","article-title":"Third-generation EGFR tyrosine kinase inhibitor for central nervous system metastases EGFR-mutant NSCLC: current evidence and future perspectives","volume":"18","author":"Li Z","year":"2023","unstructured":"Li Z, Lu S. Third-generation EGFR tyrosine kinase inhibitor for central nervous system metastases EGFR-mutant NSCLC: current evidence and future perspectives. J Thorac Oncol. 2023, 18:1625-8. 10.1016\/j.jtho.2023.09.1440","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.1143","article-title":"Central nervous system efficacy of Furmonertinib (Ast2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the furlong study","volume":"17","author":"Shi Y","year":"2022","unstructured":"Shi Y, Chen G, Wang X, et al.. Central nervous system efficacy of Furmonertinib (Ast2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the furlong study. J Thorac Oncol. 2022, 17:1297-305. 10.1016\/j.jtho.2022.07.1143","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001593","article-title":"Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report","volume":"35","author":"Jia G","year":"2024","unstructured":"Jia G, Bashir S, Ye M, Li Y, Lai M, Cai L, Xu M. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report. Anticancer Drugs. 2024, 35:542-7. 10.1097\/CAD.0000000000001593","journal-title":"Anticancer Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233198","article-title":"Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review","volume":"13","author":"Chen T","year":"2023","unstructured":"Chen T, Chen J, Liu DS, et al.. Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review. Front Oncol. 2023, 13:1233198. 10.3389\/fonc.2023.1233198","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107346","article-title":"Efficacy and safety of re-challenging 160\u00a0mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: a real-world study","volume":"184","author":"Qi R","year":"2023","unstructured":"Qi R, Fu X, Yu Y, Xu H, Shen M, He S, Lv D. Efficacy and safety of re-challenging 160\u00a0mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: a real-world study. Lung Cancer. 2023, 184:107346. 10.1016\/j.lungcan.2023.107346","journal-title":"Lung Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10676-x","article-title":"Intracranial efficacy and safety of furmonertinib 160\u2009mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy","volume":"23","author":"Xu Z","year":"2023","unstructured":"Xu Z, Hao X, Wang Q, Yang K, Li J, Xing P. Intracranial efficacy and safety of furmonertinib 160\u2009mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer. 2023, 23:206. 10.1186\/s12885-023-10676-x","journal-title":"BMC Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434843-triple-dose-furmonertinib-for-leptomeningeal-metastases-in-advanced-epidermal-growth-factor-receptor-egfr-l858r-mutated-lung-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:20:06Z","timestamp":1772274006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434843-triple-dose-furmonertinib-for-leptomeningeal-metastases-in-advanced-epidermal-growth-factor-receptor-egfr-l858r-mutated-lung-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.104428","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}